Profound Medical Corp. (TSX:PRN)
Canada · Delayed Price · Currency is CAD | Market Cap | 355.10M +53.3% |
| Revenue (ttm) | 27.10M +61.2% |
| Net Income | -46.50M |
| EPS | -1.39 |
| Shares Out | 36.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220 |
| Open | 9.80 |
| Previous Close | 9.72 |
| Day's Range | 9.80 - 9.91 |
| 52-Week Range | 5.23 - 12.40 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 21.50 (+116.95%) |
| Earnings Date | Aug 6, 2026 |
About Profound Medical
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]
Financial Performance
In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PRN stock is "Strong Buy." The 12-month stock price target is $21.50, which is an increase of 116.95% from the latest price.
News
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of...
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Is Profound Medical Corp (PROF) Positioned for Growth After Q2 Earnings Miss? GF Score: 74/100, ...
Is Profound Medical Corp (PROF) Positioned for Growth After Q2 Earnings Miss? GF Score: 74/100, Revenue at $2.5M, EPS at -$0.26
Profound Medical Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 12% year-over-year to $2.5 million, with gross margin rising to 78%. Excluding shipment timing, revenue would have been $5.6 million, up 153%. Full-year revenue is projected at $25 million (56% growth), with expanding reimbursement and a $70 million sales pipeline.
Profound Medical Earnings release: Q2 2026
Profound Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Profound Medical Quarterly report: Q2 2026
Profound Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
Profound Medical Reports Second Quarter 2026 Financial Results
– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinica...
Earnings To Watch: Profound Medical Corp (PROF) Q2 2026 -- GF Value Sees 226% Upside
Earnings To Watch: Profound Medical Corp (PROF) Q2 2026 -- GF Value Sees 226% Upside
Profound Medical upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Profound Medical (PROF) to Strong Buy from Outperform with an unchanged price target of $11.
Profound Medical upgraded to Strong Buy at Raymond James after positive data
As previously reported, Raymond James analyst Michael Freeman upgraded Profound Medical (PROF) to Strong Buy from Outperform with an unchanged price target of $11 after the company released positive i...
Robotic Radical Prostatectomy Comes Up ‘Short' in CAPTAIN Trial
– Whole-gland TULSA ablation demonstrates statistically significant superior penile length preservation compared to robotic RP at 1 month – – Whole-gland TULSA ablation demonstrates statistically sign...
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that its MRI-guided, AI-powered, Robotically-Driven and In...
Telix announces LoI to collaborate with EDAP TMS and Profound Medical
Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with EDAP TMS (EDAP) and Profound Medical (PROF), companies developing advanced minim...
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General and...
Profound Medical Corp Annual Shareholders Meeting Transcript
Profound Medical Corp Annual Shareholders Meeting Transcript
Profound Medical files to sell 921,428 common shares for holders
17:07 EDT Profound Medical (PROF) files to sell 921,428 common shares for holders
Profound Medical Registration statement: Registration filing
Profound Medical filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Profound Medical Q1 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supp...
Profound Medical price target lowered to $10 from $12 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and keeps a Buy rating on the shares.
Profound Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue doubled year-over-year to CAD 5.3 million, with improved gross margin and a narrowed net loss. Private insurer coverage expanded, clinical evidence strengthened, and 2026 revenue is guided to grow 56% to CAD 25 million, with margins of 70% or higher.
Profound Medical Earnings release: Q1 2026
Profound Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Profound Medical Quarterly report: Q1 2026
Profound Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Profound Medical Reports Strong First Quarter 2026 Financial Results
– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORO...